Back

Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 6 Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Hendrik Bonnemeier

Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)

9 More presentations in this session

Presentation thumbnail
Performance of the HAS-BLED, ATRIA, and PRECISE-DAPT Bleeding Risk Scores in Atrial Fibrillation Patients Using Antiplatelet Agents or Oral Anticoagulants
Mr J. Choi (Busan, KR)
Abstract Slides
Presentation thumbnail
Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease
Doctor J. Strange (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly asian patients with atrial fibrillation
Doctor T. Chao (Taipei, TW)
Abstract
Presentation thumbnail
Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis
Ms A. Kang (Princeton, US)
Abstract Slides
Presentation thumbnail
Risk prediction of atrial fibrillation in the community combining biomarkers and genetics
Doctor C. Boerschel (Hamburg, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources